Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
How GLP3Planner Calculates Drug Levels
referenceTechnical overview of the pharmacokinetic model behind GLP3Planner. Covers the one-compartment model with first-order absorption, the Bateman equation, drug parameters sourced from clinical trials, multi-dose superposition and steady state, the reconstitution math (BAC water to syringe units), and the standard per-compound titration ladders.
Vendor Safety Methodology: How GLP3Planner Evaluates Peptide Sourcing
referenceEditorial methodology for vendor evaluation: 40 active US peptide research-chemical vendors assessed across six criteria, third-party verified against Finnrick Analytics and Janoshik Analytical, with the market reshuffle context that changed the trust calculus in 2025-2026.